Search

Description of HLA‐B*56:01:01:05S with a point mutation at the acceptor splicing site within intron 4. [ABSTRACT FROM AUTHOR]

Response to interferon-beta (IFN-beta) treatment is heterogeneous in multiple sclerosis (MS). We aimed to search for biomarkers predicting no evidence of disease activity (NEDA) status upon IFN-beta treatment in MS. 119 patients with relapsing-remitting MS (RRMS) initiating IFN-beta treatment were included in the study, and followed prospectively for 2 years. Neutralizing antibodies (NAb) were explored in serum samples obtained after 6 and 12 months of IFN-beta treatment. Soluble cytokines and blood lymphocytes were studied in basal samples by ELISA and flow cytometry, respectively. 9% of patients developed NAb. These antibodies were more frequent in patients receiving IFN-beta 1b than in those treated subcutaneous ( p = 0.008) or intramuscular ( p < 0.0001) IFN-beta 1a. No patient showing NAb remained NEDA during follow-up. Basal immunological variables are also associated with patient response. Percentages below 3% of CD19 + CD5 + cells (AUC 0.74, CI 0.63-0.84; OR 10.68, CI 3.55-32.15, p < 0.0001; Likelihood ratio 4.28) or above 2.6% of CD8 + perforin + T cells (AUC 0.79, CI 0.63-0.96; OR 6.11, CI 2.0-18.6, p = 0.0009; Likelihood ratio 5.47) increased the probability of achieving NEDA status during treatment. Basal blood immune cell subsets contribute to identify MS patients with a high probability of showing an optimal response to IFN-beta. [ABSTRACT FROM AUTHOR]

A new HLA null allele, DRB1*15:176N, was characterized in a Spanish volunteer bone marrow donor. [ABSTRACT FROM AUTHOR]

Characterization of the novel HLA‐B*44:387 allele. [ABSTRACT FROM AUTHOR]

Genomic full‐length characterization of the HLA‐DQB1*03:25:01 allele. [ABSTRACT FROM AUTHOR]

The author claims that his name is incorrectly listed on PubMed. It seems that the first and last name has been mixed up. [ABSTRACT FROM AUTHOR]

The extended genomic sequence of HLA‐DQB1*04:59N allele. [ABSTRACT FROM AUTHOR]

Two new HLA‐DRB3 alleles were characterized, DRB3*02:151 and DRB3*03:48. [ABSTRACT FROM AUTHOR]

Characterization of the novel HLA‐A*23:125 allele. [ABSTRACT FROM AUTHOR]

Characterization of two novel HLA class I null alleles. [ABSTRACT FROM AUTHOR]

We identified a new HLA‐C allele, HLA‐C*03:03:01:32, with a splice site mutation in intron 5. [ABSTRACT FROM AUTHOR]

The novel HLA‐DQB1*04:02:01:16Q allele showing a point mutation in the intron 3. [ABSTRACT FROM AUTHOR]

Six novel HLA alleles were characterized in the Spanish population. [ABSTRACT FROM AUTHOR]

Characterization of the novel HLA‐C allele, HLA‐C*07:1000. [ABSTRACT FROM AUTHOR]

Background: The increasing number of clinical trials for induced pluripotent stem cell (iPSC)-derived cell therapy products makes the production on clinical grade iPSC more and more relevant and necessary. Cord blood banks are an ideal source of young, HLA-typed and virus screened starting material to produce HLA-homozygous iPSC lines for wide immune-compatibility allogenic cell therapy approaches. The production of such clinical grade iPSC lines (haplolines) involves particular attention to all steps since donor informed consent, cell procurement and a GMP-compliant cell isolation process. Methods: Homozygous cord blood units were identified and quality verified before recontacting donors for informed consent. CD34+ cells were purified from the mononuclear fraction isolated in a cell processor, by magnetic microbeads labelling and separation columns. Results: We obtained a median recovery of 20.0% of the collected pre-freezing CD34+, with a final product median viability of 99.1% and median purity of 83.5% of the post-thawed purified CD34+ population. Conclusions: Here we describe our own experience, from unit selection and donor reconsenting, in generating a CD34+ cell product as a starting material to produce HLA-homozygous iPSC following a cost-effective and clinical grade-compliant procedure. These CD34+ cells are the basis for the Spanish bank of haplolines envisioned to serve as a source of cell products for clinical research and therapy. [ABSTRACT FROM AUTHOR]

Five new HLA class I alleles were characterized by next‐generation sequencing. [ABSTRACT FROM AUTHOR]

Complete genomic characterization of HLA‐C*07:166. [ABSTRACT FROM AUTHOR]

Characterization of three new HLA class I alleles, B*50:73, C*08:218 and C*15:229. [ABSTRACT FROM AUTHOR]

Four new HLA alleles characterized by NGS, B*40:455, C*03:521, C*03:04:81 and DQB1*03:431. [ABSTRACT FROM AUTHOR]

Risk factors and outcomes of GF after TCD haploidentical transplantation in children with hematological malignancies were analyzed. 148 TCD transplants were included. 78 patients were diagnosed of ALL and 70 patients of AML. 22 out of 148 patients developed GF. MVA showed that patient <9 years (HR: 5.0; 95% CI: 1.1–23.0; p = 0.03) and pre-transplant CD8+ ≥150/µL (HR: 12.0; 95% CI: 1.6–95.3; p = 0.01) were associated with GF. A score was assigned to each patient. The cumulative incidence of GF for patients with CD8+ ≥150/µL (2 points) was 6 ± 4% and 3 ± 2% for patients <9 years (1 point) while for patients with 3 points was 24 ± 6%, With a median follow-up of 48 months (range; 4–180 months), 14 (64%) of 22 patients with GF are alive and disease-free. DFS for GF patients was 53 ± 12%. In conclusion, patient age and pre-transplant CD3+/CD8+ are associated with GF in children undergoing TCD haploidentical transplantation. [ABSTRACT FROM AUTHOR]

Twelve new HLA class I alleles were characterized in the Spanish population. [ABSTRACT FROM AUTHOR]

Two new HLA‐C alleles, HLA‐C*05:01:01:17 and ‐C*16:152 were detected and characterized. [ABSTRACT FROM AUTHOR]

Background: iPSC (induced pluripotent stem cells) banks of iPSC lines with homozygous HLA (human leukocyte antigen) haplotypes (haplobanks) are proposed as an affordable and off-the-shelf approach to allogeneic transplantation of iPSC derived cell therapies. Cord blood banks offer an extensive source of HLA-typed cells suitable for reprogramming to iPSC. Several initiatives worldwide have been undertaken to create national and international iPSC haplobanks that match a significant part of a population. Methods: To create an iPSC haplobank that serves the Spanish population (IPS-PANIA), we have searched the Spanish Bone Marrow Donor Registry (REDMO) to identify the most frequently estimated haplotypes. From the top ten donors identified, we estimated the population coverage using the criteria of zero mismatches in HLA-A, HLA-B, and HLA-DRB1 with different stringencies: high resolution, low resolution, and beneficial mismatch. Results: We have calculated that ten cord blood units from homozygous donors stored at the Spanish cord blood banks can provide HLA-A, HLA-B, and HLA-DRB1 matching for 28.23% of the population. Conclusion: We confirm the feasibility of using banked cord blood units to create an iPSC haplobank that will cover a significant percentage of the Spanish and international population for future advanced therapy replacement strategies. [ABSTRACT FROM AUTHOR]

Cystic Fibrosis (CF) is an inherited pleiotropic disease that results from abnormalities in the gene codes of a chloride channel. The lungs of CF patients are chronically infected by several pathogens but bacteraemia have rarely been reported in this pathology. Besides that, circulating monocytes in CF patients exhibit a patent Endotoxin Tolerance (ET) state since they show a significant reduction of the inflammatory response to bacterial stimulus. Despite a previous description of this phenomenon, the direct cause of ET in CF patients remains unknown. In this study we have researched the possible role of microbial/endotoxin translocation from a localized infection to the bloodstream as a potential cause of ET induction in CF patients. Plasma analysis of fourteen CF patients revealed high levels of LPS compared to healthy volunteers and patients who suffer from Chronic Obstructive Pulmonary Disease. Experiments in vitro showed that endotoxin concentrations found in plasma of CF patients were enough to induce an ET phenotype in monocytes from healthy controls. In agreement with clinical data, we failed to detect bacterial DNA in CF plasma. Our results suggest that soluble endotoxin present in bloodstream of CF patients causes endotoxin tolerance in their circulating monocytes. [ABSTRACT FROM AUTHOR]